ArticleJournal of animal science2025
The effect of dietary camelina, flaxseed, and canola oil supplementation on skin fatty acid profile and immune and inflammatory responses in healthy adult horses.
Article in Journal of animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Benefits ofInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Camelina sativa is an oilseed crop rich in α-linolenic acid (ALA), an n-3 fatty acid (FA), and is resistant to harsh climates and pests. Previously, supplementation with camelina oil (CAM) in horses had no adverse effects on basic health parameters and had comparable skin and coat parameters as both flaxseed oil (FLX) and canola oil (OLA). Further, the plasma FA profile of horses was reflective of their respective treatment oil. The objective of this study was to assess the effects of dietary CAM supplementation on skin FA profile, immune, and inflammatory responses as compared to 2 commonly used oils in the equine industry, OLA and FLX, in healthy adult horses. Twenty-four adult horses, from 2 separate herds, were enrolled in this experiment. The horses underwent a gradual 4-wk fat acclimation period to sunflower oil (approximately 0.28% ALA), then were supplemented with either CAM (approximately 34.9% ALA), OLA (approximately 12.0% ALA), or FLX (56.0% ALA) at an inclusion rate of 0.37 g/kg body weight (BW) per day for an additional 16 wk. Immune and inflammatory responses were assessed by measuring antibody concentrations across time after sensitization to keyhole limpet hemocyanin (KLH) at weeks 10 and 12, and a subsequent delayed-type hypersensitivity (DTH) challenge. Skin biopsy samples were collected at weeks 0, 8, and 16, and FA composition was determined using gas-chromatography. All data were analyzed as a repeated measures ANOVA using PROC GLIMMIX in SAS. Antibody and DTH responses to KLH did not differ among groups (P = 0.262 and 0.813, respectively), and no treatment by time effects were observed (P = 0.764 and P = 0.817, respectively). Most FA in the skin changed in composition across time, with the sum of n-3 FA increasing (P < 0.001) and the sum of n-6 FA and skin n-6:n-3 ratio decreasing over time (P < 0.001 and P < 0.001, respectively). Only dihomo-γ-linolenic acid (P = 0.025) and the sum of n-3 FA (P = 0.031) had treatment-by-week effects. At week 16, the composition of eicosapentaenoic acid in the skin was greater in FLX than OLA, but neither differed from CAM (P = 0.049). These results suggest that ALA supplementation may beneficially impact skin FA profile. However, due to the small differences in n-3 FA and n-6:n-3 ratio among CAM, FLX, and OLA, a comparable skin FA profile, immune, and inflammatory response was observed among treatments at a dose of 0.37 g oil/kg BW. Therefore, CAM may be a suitable alternative to FLX in equine diets for the delivery of ALA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.